LLY Form 4: Zakrowski Sells 1,000 Shares at $734.93
Donald A. Zakrowski, Senior Vice President, Finance & Chief Accounting Officer at Eli Lilly & Co. (LLY), reported a sale of 1,000 shares of Eli Lilly common stock on 08/28/2025 at a price of $734.93 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Donald A. Zakrowski, Senior Vice President, Finance & Chief Accounting Officer at Eli Lilly & Co. (LLY), reported a sale of 1,000 shares of Eli Lilly common stock on 08/28/2025 at a price of $734.93 per share. The filing states the sale was executed under a Rule 10b5-1 trading plan adopted on November 20, 2024. After the transaction, the reporting person beneficially owned 3,839.659 shares directly and 1,725.72 shares indirectly (401(k)). The Form 4 was signed by an authorized representative on behalf of Mr. Zakrowski.
Insights
TL;DR: Routine insider sale under a pre-established 10b5-1 plan; transaction size is small relative to typical institutional stakes.
The sale of 1,000 shares at $734.93 appears to be a preplanned disposition under a Rule 10b5-1 trading plan adopted 11/20/2024, which generally reduces timing-related informational concerns. The filing discloses post-transaction beneficial ownership of 3,839.659 shares directly and 1,725.72 shares indirectly via a 401(k). There is no disclosure of options exercised or derivative activity in this Form 4. From a financial-materiality perspective, the reported sale is modest in size and does not, on its face, imply a change to the company’s operating outlook or capital structure.
TL;DR: Governance-wise this is a standard, pre-authorized insider sale with appropriate disclosure and authorization.
The transaction is documented as executed pursuant to a Rule 10b5-1 trading plan, which is a commonly used mechanism for insiders to transact while limiting potential insider trading concerns. The Form 4 includes the reporting person’s title (SVP, Finance & CAO) and shows the signature was provided by an authorized representative. There are no amendments or additional governance flags noted in the filing. The information provided is procedural and routine.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,000 | $734.93 | $735K |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2024.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Donald A. Zakrowski report for LLY?
Was the sale by Zakrowski a planned transaction?
What is Zakrowski’s role at Eli Lilly as stated in the filing?
Who signed the Form 4 filing for Zakrowski?
AI-generated analysis. How Rhea-AI works. Not financial advice.